Drug Database
CE

cefazolin dibenzylamine (Daren)

✓ Approved

Pfizer, Inc. · Small Molecule · Small Molecule

What is cefazolin dibenzylamine?

cefazolin dibenzylamine is a small molecule developed by Pfizer, Inc.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesDaren
CompanyPfizer, Inc.
Drug ClassSmall Molecule
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Pfizer, Inc.

Therapeutic Indications

cefazolin dibenzylamine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsUrinary tract infection✓ Approved
Infections and infestationsRespiratory tract infection✓ Approved

Related Research Articles

PubMedInternational urogynecology journal2026-10-15

Postoperative Infection Risk in Sacrocolpopexy: Single vs Dual Antibiotic Prophylaxis.

Mikhail Susana Mustafa SM, Francis Yara Nakhleh YN, Karram Jawad J, Polishook Zvi Y ZY et al.

The optimal antibiotic prophylaxis for mesh-based prolapse surgery remains uncertain. Although cefazolin is widely used, its limited anaerobic coverage may increase the risk of postoperative infections, particularly in women undergoing concomitant hysterectomy. Evidence from hysterectomy cohorts suggests that adding metronidazole reduces surgical-site infections, prompting evaluation of this approach in laparoscopic mesh-augmented apical prolapse repair. The objective was to compare postoperative infection rates in women receiving single-agent versus dual-agent prophylactic antibiotics. This retrospective cohort study included women with pelvic organ prolapse who underwent laparoscopic mesh-augmented apical prolapse repair between 2021 and 2025. Patients received either cefazolin alone or cefazolin plus metronidazole according to the routine practice of the operating urogynecologist. Demographic, operative, and postoperative data were extracted from electronic medical records. The primary outcome was composite postoperative infection within 30 days, including postoperative fever, surgical site or trocar site infection, mesh infection, pelvic abscess, or urinary tract infection. Associations between prophylactic regimen and postoperative infection were evaluated using univariable analyses. The antibiotic prophylaxis regimen was surgeon dependent, with one surgeon routinely administering cefazolin alone and the other cefazolin plus metronidazole. Multivariable logistic regression was performed to adjust for baseline differences between the groups. A total of 523 women met the inclusion criteria; 204 (39.0%) received dual prophylaxis and 319 (61.0%) received cefazolin alone. Overall composite postoperative infection outcome occurred in 18 out of 523 patients (3.4%). Infection rates of the single-agent and dual-prophylaxis groups were similar (3.7% vs 2.9%, p = 0.64). Rates of postoperative fever, surgical-site infection, and urinary tract infection did not differ significantly between groups. No mesh-related infections or pelvic abscesses were observed. After adjustment for baseline differences, the antibiotic regimen was not significantly associated with the composite postoperative infection outcome (aOR 1.30, 95% CI 0.36-4.64; p = 0.689). Composite postoperative infection outcome rates after laparoscopic sacrocolpopexy were low, with no significant difference observed between cefazolin alone and combined cefazolin-metronidazole prophylaxis.

PMID 42878791
Read full article →
PubMedJournal of neurosurgical anesthesiology2026-10-15

Immediate Perioperative Hypersensitivity and Anaphylaxis in Neuroanesthesia Practice: A Focused Review.

Manlapaz Mariel M, Farag Ehab E

Perioperative hypersensitivity reactions are uncommon but potentially catastrophic. Neurosurgical and spine patients are especially vulnerable, as the injured brain and spinal cord tolerate anaphylaxis-induced hypotension poorly, cerebral and spinal perfusion may fall precipitously, and draping of the head and torso may obscure cutaneous signs. These procedures also rely heavily on topical hemostatic agents. National audits estimate the incidence of perioperative anaphylaxis at roughly 1 in 5000 to 10,000 anesthetics, but estimates vary geographically. No study has reported a denominator-based incidence confined to neurosurgery, leaving the true burden uncharacterized for this surgical specialty. This focused review summarizes the agents, mechanisms, and perioperative implications of immediate hypersensitivity and anaphylaxis relevant to neuroanesthesia. Immediate reactions are immunologic (IgE-mediated, or IgG- and complement-mediated) or nonimmunologic (direct mast-cell activation) but converge on mast-cell and basophil mediator release, which renders their presentations largely indistinguishable. We examine agents of relevance to neurosurgery, including neuromuscular blocking agents, cefazolin and other β-lactams, chlorhexidine, sugammadex, gelatin-based and other hemostatic agents, protamine, tranexamic acid, fluorescent and dye agents, and iodinated contrast media-alongside their mechanisms and safer alternatives. Management follows international consensus recommendations centered on prompt epinephrine administration and fluid resuscitation titrated to severity. Antihistamines and corticosteroids are useful adjuncts but should not delay resuscitation. Improved outcomes depend on greater awareness, careful allergy assessment and appropriate de-labeling, surgical-anesthesia communication, and wider access to testing and dedicated surveillance.

PMID 42878097
Read full article →
PubMedFrontiers in health services2026-10-15

Antibiotic prescribing appropriateness among critically ill patients at a single tertiary care center in the United Arab Emirates: a retrospective cohort study.

Kassis Inas I, Al Balas Mosab M, Rashid Sheilla Hilal Hamed SHH, Gulam Shabaz Mohiuddin SM et al.

Despite expanding antimicrobial stewardship initiatives, evidence evaluating the appropriateness of antibiotic prescribing and its clinical implications in intensive care settings in the United Arab Emirates remains limited. This study aimed to assess the appropriateness of antibiotic prescribing among intensive care unit patients, identify factors associated with appropriate antibiotic therapy, and examine its association with clinical outcomes. A retrospective cohort study was conducted in the intensive care unit of a tertiary care hospital in the Emirate of Abu Dhabi. Adult patients aged 18 years or older who were admitted between January 2023 and December 2024, had a length of stay exceeding 24 h but less than 30 days, received at least one systemic antibiotic, and had complete medical records were included. Data were extracted from electronic medical records and a regional health information exchange platform. Antibiotic appropriateness was evaluated against institutional or Infectious Diseases Society of America guidelines. Overall, 36% of patients received inappropriate antibiotic therapy. The most common reason for inappropriateness was the absence of a clear indication, particularly for postoperative prophylaxis (44.4%). At the individual agent level, cefepime (48.2%), metronidazole (36.2%), and cefazolin (33.9%) exhibited the highest rates of inappropriate use. Multivariable logistic regression identified positive microbiological culture results (AOR = 3.34, p < 0.001) and sepsis (AOR = 2.12, p = 0.002) as factors independently associated with higher odds of appropriate antibiotic use. Conversely, the presence of a central venous catheter (AOR = 0.30, p = 0.003) was associated with lower odds of appropriate antibiotic use. Appropriate antibiotic therapy was associated with higher odds of organ dysfunction (AOR = 1.69, p = 0.032), nosocomial infection (AOR = 2.28, p = 0.005), and persistent infection despite therapy (AOR = 2.13, p = 0.005). Approximately one-third of patients received inappropriate antibiotic therapy, representing a substantial antimicrobial stewardship concern despite the observed strengths in culture-guided therapy and infection-focused management.

PMID 42876967
Read full article →
PubMedNihon Hinyokika Gakkai zasshi. The japanese journal of urology2026-10-13

[ANAPHYLACTIC SHOCK DUE TO REMIFENTANIL DURING GENDER-AFFIRMING SURGERY: A CASE REPORT].

Yamana Azusa A, Ichihara Koji K, Ito Kaoru K, Fukazawa Takeshi T et al.

A person in their twenties, assigned male at birth and diagnosed with gender incongruence, underwent gender-affirming surgery (GAS) after starting hormone therapy. Orchiectomy, penectomy, labiaplasty and vaginoplasty were planned. The preoperative evaluation revealed no contraindications to general anesthesia. Induction was performed with sevoflurane, propofol, fentanyl, remifentanil, and rocuronium. Cefazolin was administered as a prophylactic antibiotic. After bilateral orchiectomy, the patient developed rapidly worsening urticaria, wheezing, decreased oxygen saturation and hypotension. Anaphylaxis was diagnosed, and emergency treatment stabilized respiratory and circulatory function. Because the cause was unknown, the operation was paused. The patient was moved to the intensive care unit. Symptoms resolved within hours and the patient was discharged on the second postoperative day. Subsequent allergy testing, including prick and intradermal tests for anesthetics and antibiotics, revealed a positive intradermal response to remifentanil, which identified it as the cause. After detailed counseling, the patient and their family strongly wished to complete GAS, and reoperation was performed without remifentanil. The postoperative course was uneventful.

PMID 42864031
Read full article →
PubMedThe Annals of pharmacotherapy2026-10-12

Retrospective Evaluation of the Association of Hypoalbuminemia With Acute Treatment Outcomes in Methicillin-Susceptible Staphylococcus Aureus Bacteremia.

Stevens Ryan W RW, DeSimone Daniel C DC, Hess Kyle A KA, Hindy Joya-Rita JR et al.

Cefazolin and antistaphylococcal penicillins (ASP) are first-line agents for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. These agents are substantially protein-bound; however, scant data exist evaluating the impact of hypoalbuminemia on microbiologic and patient outcomes for this indication. The purpose of this study was to assess whether hypoalbuminemia is associated with delayed blood culture clearance in patients with MSSA bacteremia being treated with cefazolin or ASPs as definitive therapy. This retrospective cohort study included patients admitted for MSSA bacteremia between January 1, 2006 and December 31, 2019, with a serum albumin obtained between the date of an initial positive blood culture result and 72 hours following initiation of definitive therapy with cefazolin or an ASP. The primary outcome was the rate of persistently positive blood cultures, defined as failure to clear blood cultures within 72 hours of definitive therapy initiation. Patients with a serum albumin ≤2.5 g/dL were compared with those with an albumin >2.5 g/dL. Propensity score weighting was used to account for differences in cohort characteristics. A total of 123 patients were included. After propensity score weighting, patients with hypoalbuminemia had a higher rate of persistently positive blood cultures, both in the overall cohort (45.0% vs 13.2%, P < .001) and in the subgroups of cefazolin (33.0% vs 9.1%, P = .015) and ASP (60.1% vs 18.3%, P = .001) when analyzed separately. After propensity weighting in the combined cohort, the length of stay was longer in the hypoalbuminemic cohort, but no differences in mortality were observed. Hypoalbuminemia was associated with a delayed 72-hour blood culture clearance in patients with MSSA bacteremia treated with either cefazolin or ASPs.

PMID 42860811
Read full article →
PubMedInfectious diseases & clinical microbiology2026-10-12

Peritoneal Dialysis-Associated Peritonitis due to Pasteurella multocida: A Rare Case of Stray-Animal Exposure and Fluoroquinolone Resistance.

Özdemir Melih Tarık MT, Arıcı Neslihan N, Şenol Elif Gülcan EG, Kızılhan Refia R et al.

Pasteurella multocida, a Gram-negative coccobacillus commonly found in the oropharyngeal flora of cats, is a rare cause of peritoneal dialysis-associated peritonitis. We report the case of a 44-year-old patient with exposure to stray cats who presented with abdominal pain and cloudy dialysis effluent. Laboratory tests showed leukocytosis and elevated C-reactive protein (CRP), and we initiated empirical intraperitoneal cefazolin therapy. Peritoneal fluid culture yielded P. multocida, which was resistant to fluoroquinolones but susceptible to penicillin, cefotaxime, trimethoprim-sulfamethoxazole, and tetracycline. The patient showed rapid clinical improvement. This case highlights the importance of assessing animal exposure in patients undergoing peritoneal dialysis and underscores the emergence of antimicrobial resistance in P. multocida within a One Health framework.

PMID 42861251
Read full article →

+6308 more articles available with a free account

Sign up free to view all articles →

Ask about cefazolin dibenzylamine